Chemed Corporation (NYSE:CHE) Receives Consensus Recommendation of "Hold" from Analysts
Chemed Corporation (NYSE:CHE) has received a consensus "Hold" recommendation from analysts, with an average 12-month price target of $501.50. Recent analyst actions have been mixed, including some downgrades to "Hold" or "Sector Perform" and some upgrades. The company reported better-than-expected quarterly EPS of $5.65 and declared a $0.60 quarterly dividend, while noteworthy insider share sales by the CEO and a director also occurred.
ETFs Investing in Chemed Corporation Stocks
This article lists various ETFs that include Chemed Corporation (CXM) stocks in their holdings. It provides a detailed table with information for each ETF, including market value, weight of CXM in the fund, issuer, management style, focus, expense ratio, assets under management (AUM), price, percentage change, relative volume, and 3-year NAV total return. The ETFs cover a range of investment focuses such as mid-cap, small-cap, total market, and health care.
Discipline and Rules-Based Execution in CHE Response
This article provides an AI-generated analysis of Chemed Corp (NYSE: CHE), noting strong near and mid-term sentiment and compelling upside potential due to a lack of resistance levels above the current price. It outlines three distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss points tailored to different risk profiles. The analysis also includes multi-timeframe signal analysis, identifying support and resistance levels across near, mid, and long-term horizons.
Activist Barington targets healthcare firm Chemed
Barington Capital Group, an activist investor, has taken a stake in healthcare firm Chemed. The activist fund is known for pushing for corporate changes and improvements in shareholder value. Further details about Barington's specific demands or plans for Chemed were not immediately available.
Chemed Corp stock hits 52-week high at $484.86 By Investing.com
Chemed Corp's stock recently hit a new 52-week high of $484.86, reflecting positive investor sentiment and steady growth, with shares trading just under its 52-week peak. The company has shown a 1.63% increase over the past year and more significant returns of 13.77% over six months and 12.69% year-to-date. This surge follows impressive first-quarter earnings for 2026, which surpassed analyst expectations, leading RBC Capital to raise its price target for the company.
Boston Trust Walden Corp Trims Position in Chemed Corporation $CHE
Boston Trust Walden Corp reduced its stake in Chemed Corporation (NYSE:CHE) by 7.3% in the first quarter, selling 16,044 shares and retaining 205,197 shares valued at $77.5 million. Chemed recently reported stronger-than-expected quarterly earnings with an EPS of $5.65, though revenue slightly missed estimates at $657.5 million. Analysts maintain a cautious outlook with an average "Hold" rating and a mean price target of $501.50, despite some recent price target increases.
Chemed Corp stock hits 52-week high at $484.86
Chemed Corp's stock recently reached a 52-week high of $484.86, trading just under its peak of $486.57. This growth reflects positive investor sentiment, with the stock increasing by 1.63% over the past year, 13.77% over six months, and 12.69% year-to-date. The company also surpassed analyst expectations with strong first-quarter 2026 earnings, leading RBC Capital to raise its price target.
Chemed Corp stock hits 52-week high at $484.86
Chemed Corp (NYSE:CHE) stock reached a new 52-week high of $484.86, trading just under its peak of $486.57. This reflects a modest 1.63% increase over the past year, but more significant gains of 13.77% over six months and 12.69% year-to-date. The company also reported strong Q1 2026 earnings, surpassing analyst expectations, with RBC Capital raising its price target.
Chemed Corp highlights steady healthcare and services footprint. Investors focus on long-term earnin
Chemed Corp operates a unique dual business model, combining hospice and palliative care with residential and commercial services like plumbing and drain cleaning. This structure attracts investors seeking diversified, defensive cash flows by blending a healthcare segment driven by an aging population with a services segment addressing recurring maintenance needs. The company navigates distinct operational and regulatory environments for each segment, aiming for long-term earnings growth through strategic capital allocation and continuous operational improvement.
Chemed Corp stock hits 52-week high at $484.86
Chemed Corp stock recently hit a 52-week high of $484.86, with shares trading just under its peak of $486.57. The company has shown positive momentum, with a 13.77% return over six months and a 12.69% year-to-date gain, supported by strong first-quarter earnings that surpassed analyst expectations. Analysts view Chemed's financial health as "GREAT," and RBC Capital recently raised its price target for the stock.
Chemed To Report Second Quarter 2026 Earnings July 28, Related Conference Call To Be Held On July 29
Chemed Corporation has announced it will release its second-quarter 2026 financial results on Tuesday, July 28, 2026, after the market close. The company will host a conference call and webcast on Wednesday, July 29, 2026, at 10 a.m. ET to discuss the results and provide a business update. Chemed operates two subsidiaries, VITAS Healthcare and Roto-Rooter, and is listed on the New York Stock Exchange under the ticker CHE.
Chemed Corp (CHE) Shares Surge 3.2% -- What GF Score of 86 Tells Investors
Chemed Corp (CHE) shares recently surged 3.2% to $480.87, yet the stock remains "Modestly Undervalued" according to GuruFocus' GF Value™ of $662.41. The company boasts a strong GF Score™ of 86/100, reflecting robust financial strength, profitability, growth, and valuation, despite a lower momentum rank of 4/10. Investors should consider the recent insider selling of $1.7 million without any buying activity, which could signal caution despite the attractive valuation.
Chemed To Report Second Quarter 2026 Earnings July 28, Related Conference Call To Be Held On July 29
Chemed Corporation announced it will release its financial results for the second quarter ended June 30, 2026, on Tuesday, July 28, 2026, after the New York Stock Exchange closes. The company will host a conference call and webcast on Wednesday, July 29, 2026, at 10 a.m. ET, to discuss these results and provide a business update. Chemed operates two wholly-owned subsidiaries, VITAS Healthcare and Roto-Rooter.
Fort Washington Investment Advisors Inc. OH Has $23.52 Million Stake in Chemed Corporation $CHE
Fort Washington Investment Advisors Inc. OH increased its stake in Chemed Corporation by 20.3% in Q1, now holding 62,264 shares valued at $23.52 million. Chemed reported better-than-expected Q1 earnings of $5.65 per share, though revenue slightly missed estimates. The company recently paid a quarterly dividend of $0.60 per share, and analysts currently rate the stock a "Hold."
Price to earnings forward of Chemed Corp – NYSE:CHE
This article provides a brief overview of Chemed Corp (NYSE: CHE) financials, specifically focusing on its forward price-to-earnings ratio. It appears to be a stub or partial financial data page from TradingView. The content is sparse, highlighting general financial information without specific numerical data.
Price to sales forward of Chemed Corp – NYSE:CHE
This article provides financial information for Chemed Corp (NYSE:CHE), focusing on its forward price-to-sales ratio. It appears to be a stub or a section of a larger financial data platform, indicating the period, value, and change of this financial metric for the company.
Chemed Corporation Actuals & Estimates (NYSE:CHE)
This article provides a comprehensive overview of Chemed Corporation (NYSE: CHE) financials, stock performance, and analyst estimates. It covers historical price data, future price forecasts, earnings, revenue, dividends, and other key financial indicators to help investors make informed decisions.
Enterprise value to EBIT forward of Chemed Corp – NYSE:CHE
The article provides a snapshot of Chemed Corp's (NYSE: CHE) enterprise value to EBIT forward. It is presented in a data-centric view from TradingView, focusing on key financial metrics for investors and analysts. The content is sparse, indicating it's likely a data point within a larger financial platform.
Enterprise value to revenue forward of Chemed Corp – NYSE:CHE
This article provides financial data for Chemed Corp (NYSE: CHE), specifically its enterprise value to revenue forward. It appears to be a snapshot of financial metrics for the company, accessible through TradingView. The content itself is terse, presenting a specific financial ratio without additional commentary.
Enterprise value to EBITDA forward of Chemed Corp – NYSE:CHE
This article focuses on the enterprise value to EBITDA forward for Chemed Corp (NYSE: CHE). It indicates that the market is currently closed with no trades, and provides navigation to various financial data, news, and technical analysis tools for the stock on TradingView.
VITAS Healthcare Hospice Services from Chemed Corp - quiet support for complex end-of-life care in the US
VITAS Healthcare, a subsidiary of Chemed Corp, is a leading provider of end-of-life care in 14 US states, offering interdisciplinary hospice services at home or in inpatient units. The company specializes in complex cases, providing extensive support including 24/7 on-call nurses and bereavement services. Its operations are closely watched by investors due to its significant contribution to Chemed's revenue, with growth driven by occupancy, service expansion, and staffing stability.
Chemed Corp (CHE) Stock Analysis: Evaluating Its Potential Upside for Healthcare Investors
Chemed Corp (NYSE: CHE) operates two distinct business segments: VITAS Healthcare (hospice and palliative care) and Roto-Rooter (plumbing and drain cleaning), giving it a diversified revenue stream. The company boasts a strong return on equity of 25.60% and a healthy free cash flow, with a forward P/E ratio of 16.21 suggesting reasonable valuation. While analyst ratings are cautiously optimistic with a modest target price upside, technical indicators like a low RSI suggest the stock might be oversold, presenting a potential opportunity for contrarian investors.
Chemed Corp (CHE) Institutional Confidence
Chemed Corp (CHE) has an institutional shareholding score of 10.00, placing it first among 76 companies in the Healthcare Providers & Services industry. Institutional shareholding decreased by 5.94% quarter-over-quarter, with the largest shareholder, ETHSX, increasing its holdings by 1423.67%. BlackRock Institutional Trust Company and Kayne Anderson Rudnick Investment Management are among the other significant institutional holders.
Chemed Stock - Long-term hospice and plumbing model under review
Chemed Corp's stock is under review, focusing on its unique dual business model combining VITAS hospice care and Roto-Rooter plumbing services. Investors are assessing how this structure supports long-term growth and resilience, given the differing dynamics of healthcare and plumbing sectors. The article highlights the company's valuation, market capitalization, and the balance between stable hospice reimbursement and Roto-Rooter's market-exposed operations.
Chemed Stock - Long-term hospice and plumbing specialist in focus
Chemed Corp combines the hospice care provider VITAS and the plumbing services group Roto-Rooter. The article highlights that while there are no fresh headlines for the company, its dual business model provides long-term stability by balancing exposure to healthcare reimbursement trends and consumer service spending. VITAS serves as the primary earnings driver, while Roto-Rooter offers diversification and counteracts potential swings in healthcare admissions.
Chemed Stock - weekly review and sector backdrop for VITAS and Roto-Rooter
This article provides a weekly review of Chemed stock, the parent company of hospice provider VITAS Healthcare and plumbing service Roto-Rooter. The stock experienced modest price swings with no new company-specific headlines, trading in line with its hospice and US health services peers. The sector backdrop includes discussions around Medicare reimbursement and shifting care models, which influence the performance of Chemed and its counterparts.
Chemed Corp (CHE) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides a historical overview of Chemed Corp (CHE) dividends, detailing past and upcoming payout dates, record dates, ex-dividend dates, and dividend amounts. It shows that Chemed Corp has distributed a total of 94.63 million USD in dividends over the past five years. The article also includes current market data for CHE, such as its market capitalization and P/E ratio, but notes that there is no stock split data available.
Chemed Corp (CHE) Earnings Forecast: Future EPS & Revenue Growth Estimates
Chemed Corp (CHE) has an earnings forecast score of 7.00, ranking 47th in the Healthcare Providers & Services industry. Analysts have set an average price target of $576.00, with a high of $595.00 and a low of $550.00, and most recommend a "Buy" trend. The company's expected revenue for the next quarter is $665.53 million, and EPS for the next quarter is projected at $5.62, up from $5.49 in the previous quarter.
(CHE) Movement Within Algorithmic Entry Frameworks
This article analyzes Chemed Corp (NYSE: CHE) using algorithmic entry frameworks. It notes stable neutral readings in shorter horizons, potentially easing a long-term weak bias, and identifies a mid-channel oscillation pattern. The analysis presents three institutional trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss levels, along with a multi-timeframe signal analysis.
Chemed Corp director Andrea R. Lindell sells $602,553 in stock.
Andrea R. Lindell, a director at Chemed Corp, sold 1,347 shares of the company's capital stock for $602,553 on June 9, 2026. Following the sale, she directly holds 4,578 shares. Despite the insider sale, InvestingPro Tips indicate Chemed has raised its dividend for 17 consecutive years, and the company recently reported strong first-quarter 2026 earnings, exceeding analyst expectations.
Chemed Corp director Andrea R. Lindell sells $602,553 in stock. By Investing.com
Chemed Corp director Andrea R. Lindell sold 1,347 shares of the company's capital stock for $602,553 on June 9, 2026, at a price of $447.33 per share. Despite this insider sale, Chemed Corp maintains a "GOOD" financial health rating and has raised its dividend for 17 consecutive years. The company recently reported strong Q1 2026 earnings, surpassing analyst expectations, and RBC Capital raised its price target for the stock.
Director Andrea Lindell Sells 1,347 Shares of Chemed Corp (CHE)
Andrea Lindell, a Director at Chemed Corp (CHE), sold 1,347 shares of the company on June 9, 2026, reducing her holdings to 4,578 shares. Over the past year, Chemed Corp has seen 1 insider buy and 11 insider sells. The stock is currently trading at $447.33, and with a GF Value of $657.24, it is considered significantly undervalued, showing a price-to-GF-Value ratio of 0.68.
Roto-Rooter Buys Franchise Territory in Corpus Christi, Rio Grande Valley, and Beaumont, Texas
Roto-Rooter, a subsidiary of Chemed Corporation, has acquired a formerly independent Roto-Rooter franchise in south Texas for approximately $12.0 million. This acquisition expands its service area to include 21 counties, encompassing major cities like Corpus Christi, McAllen, Laredo, and Brownsville. Chemed Corporation operates both VITAS Healthcare, the largest provider of end-of-life hospice care, and Roto-Rooter, a leading plumbing and drain cleaning service.
Roto-Rooter Buys Franchise Territory in Corpus Christi, Rio Grande Valley, and Beaumont, Texas
Roto-Rooter Services Company, a subsidiary of Chemed Corporation, has acquired a Roto-Rooter franchise in south Texas for approximately $12.0 million. This acquisition covers 21 counties, including major cities like Corpus Christi, McAllen, Laredo, and Brownsville. Chemed Corporation's other subsidiary, VITAS Healthcare, is the largest provider of end-of-life hospice care in the nation.
Roto-Rooter Buys Franchise Territory in Corpus Christi, Rio Grande Valley, and Beaumont, Texas
Roto-Rooter Services Company, a subsidiary of Chemed Corporation (NYSE: CHE), has acquired an independent Roto-Rooter franchise in South Texas for approximately $12.0 million. This acquisition expands their service area to 21 counties, including major cities like Corpus Christi, McAllen, Laredo, and Brownsville. Chemed Corporation, headquartered in Cincinnati, Ohio, operates both VITAS Healthcare and Roto-Rooter, positioning itself as a leading provider in both hospice care and plumbing services.
ETFs Investing in Chemed Corporation Stocks
This article provides a list of Exchange Traded Funds (ETFs) that hold Chemed Corporation (CXM) stocks, sorted by market value. It details various ETFs, their issuers, management styles, expense ratios, assets under management (AUM), and performance metrics like price change and NAV total return over three years. The information aims to help investors identify funds that offer diversified exposure to Chemed Corporation.
TD Asset Management Inc Has $138.86 Million Stock Holdings in Chemed Corporation $CHE
TD Asset Management Inc. increased its stake in Chemed Corporation by 7.5% in the fourth quarter, holding shares valued at $138.86 million. Chemed reported strong quarterly earnings of $5.65 per share, exceeding estimates, and reaffirmed its FY 2026 EPS guidance. The company also declared a quarterly dividend of $0.60 per share, while analyst sentiment remains mixed with a consensus "Hold" rating.
Activist Barington targets healthcare firm Chemed
Activist investor Barington Capital Group has targeted healthcare firm Chemed, proposing a spin-off of its VITAS hospice care unit. Chemed Group, which also owns Roto-Rooter, has seen its shares underperform recently while other hospice providers have performed better. Barington believes separating VITAS could unlock significant value for Chemed shareholders.
CHE Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides an in-depth financial analysis of Chemed Corp (CHE), detailing its revenue breakdown, profitability margins, and competitive position. It highlights that "Short-term core" is CHE's largest revenue contributor, and the company maintains solid margins, including a 30.25% gross margin. The analysis also benchmarks CHE against competitors like PACS and BKD, demonstrating its relative efficiency and market capitalization of $5.61B.
How (CHE) Movements Inform Risk Allocation Models
This article analyzes Chemed Corp (NYSE: CHE) using AI models, identifying a mixed sentiment alignment and a mid-channel oscillation pattern. It presents an exceptional 33.7:1 risk-reward short setup and outlines three institutional trading strategies tailored to different risk profiles: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy. The analysis also includes multi-timeframe signal analysis, showing varying signal strengths and support/resistance levels across near-term, mid-term, and long-term horizons.
Chemed Corp (CHE) Stock Analysis: Evaluating a Healthcare Giant with a Potential 4.71% Upside
Chemed Corp (CHE) operates a dual-segment business model encompassing VITAS Healthcare and Roto-Rooter services, holding a market cap of $5.66 billion. Despite recent slight dips, analysts project a 4.71% upside with an average target price of $446.50, supported by robust financials like a 25.60% Return on Equity and $348 million in free cash flow. While technical indicators suggest short-term bearish trends, its unique market positioning and strong financial health offer an intriguing long-term investment proposition.
CHE Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Chemed Corp (CHE), indicating a "Strong Sell" consensus based on various technical indicators. It details momentum indicators like RSI and MACD, support and resistance levels, and performance relative to moving averages, offering insights into short-term momentum and long-term trends.
Chemed Corporation to Present at the 2026 RBC Global Healthcare Conference
Chemed Corporation announced it will present at the 2026 RBC Capital Markets Global Healthcare Conference on Wednesday, May 20, 2026, at 8:30 a.m. (ET) in New York City. An audio webcast of the presentation will be available on the company's investor relations website, with a replay accessible for 90 days. Chemed operates two wholly-owned subsidiaries: VITAS Healthcare and Roto-Rooter.
Chemed director Walsh sells $218,915 in stock
Chemed director George J. Walsh III sold 500 shares of CHEMED CORP (NYSE:CHE) stock for $218,915 on May 29, 2026. Following the transaction, Walsh directly holds 3,209 shares and indirectly holds 434 shares. This sale happened after Chemed reported strong first-quarter 2026 financial results, exceeding analyst expectations for both EPS and revenue.
Chemed director Walsh sells $218,915 in stock
Chemed director George J. Walsh III sold 500 shares of CHEMED CORP (NYSE:CHE) stock on May 29, 2026, totaling $218,915 at $437.83 per share. Despite the sale, Walsh still directly holds 3,209 shares and indirectly 434 shares. The company has a strong financial record, maintaining dividends for 56 years and raising them for 17 consecutive years, with recent Q1 2026 earnings surpassing analyst expectations.
Chemed (NYSE: CHE) director sells 500 shares in open-market trade
Chemed Corp director George J. Walsh III reported an open-market sale of 500 shares of Chemed capital stock at a price of $437.83 per share. Following this transaction, he directly holds 3,209 shares and indirectly holds 434 shares through his spouse. The filing indicates a net-sell position of 500 shares for the reporting period, representing a moderate impact and negative sentiment on the stock.
Chemed Corp (CHE) Stock Report: Navigating Valuation with a 25.60% ROE and a Modest Upside
Chemed Corp (NYSE: CHE) is a healthcare sector player known for its hospice and palliative care services (VITAS) and plumbing services (Roto-Rooter). The company shows a robust 25.60% return on equity and healthy free cash flow, with a modest 1.63% potential upside according to analysts. Despite its stability and strong performance metrics, the stock reflects a cautious outlook amidst market uncertainties, suggesting it as a reliable long-term investment rather than one offering immediate high returns.
Shareholders at Chemed (NYSE: CHE) vote down pay plan but back board
At Chemed Corporation's annual meeting on May 18, 2026, shareholders re-elected all director nominees and ratified PricewaterhouseCoopers LLP as independent accountants for the upcoming year. However, a significant majority voted against the non-binding proposal to approve the company’s executive compensation program, indicating shareholder dissatisfaction with current pay practices. Despite the rejection of the executive pay plan, the board maintains continuity and external financial oversight.
Trading Systems Reacting to (CHE) Volatility
This article from Stock Traders Daily discusses the volatility surrounding Chemed Corp (NYSE: CHE), noting a potential shift from positive near-term sentiment and a lack of clear price positioning signals. It highlights elevated downside risk due to the absence of long-term support signals. The report provides AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to manage CHE's volatility.
Chemed (NYSE: CHE) director awarded 386 shares of company stock
Chemed (NYSE: CHE) director George J. Walsh III was awarded 386 shares of company stock at a price of $440.77 per share as a compensation-related grant on May 18, 2026. Following this transaction, Walsh directly holds 3,709 shares, with an additional 434 shares held indirectly by his spouse. The Form 4 filing details this stock award and clarifies it as a grant rather than an open-market purchase or sale.
